雾化吸入布地奈德混悬液治疗COPD急性加重期的临床观察  

Clinical Observation of Inhaling Nebulization Budesonide Suspension on AECOPD

作　　者：叶胜兰[1] 李承红[1] 

机构地区：[1]江汉大学附属医院呼吸科,湖北武汉430015

出　　处：《江汉大学学报（自然科学版）》2011年第1期78-81,共4页Journal of Jianghan University：Natural Science Edition

摘　　要：目的:探讨雾化吸入布地奈德(普米克令舒)治疗慢性阻塞性肺疾病急性加重期(AECOPD)的疗效,并与使用口服糖皮质激素(强的松)的疗效和安全性比较.方法:通过随机分组,92例患者分为A、B、C 3组.3组均采用抗感染、茶碱平喘、吸氧、吸痰等常规治疗,A组为布地奈德混悬液(普米克令舒)雾化吸入组(n=31);B组口服强的松组(n=31);C组对照组(n=30)仅以常规治疗为主.对治疗前(H0)、治疗开始后24 h(H24)、7 d(D7)临床症状评分、St George's呼吸问卷(SGRQ)生命质量评分、最大峰值流速(PEF)占预计值百分比、FEV1/用力肺活量(FVC)、血气分析进行对比,同时观察激素相关不良反应.结果:3组病例在治疗前(H0)差异无统计学意义(P>0.05);在治疗开始后24h(H24)、7 d(D7)A组和B组均有明显改善,但两组之间差异无统计学意义(P>0.05).A组副作用明显少于B组.相对前两组而言,C组对照组上述观察指标治疗后较治疗前有所改善,但与A组或B组比较差异有统计学意义(P<0.05).结论:布地奈德混悬液雾化吸入治疗慢性阻塞性肺疾病,可缩短病程,疗效确切,且方便、安全,可作为治疗慢性阻塞性肺疾病的主要药物.布地奈德混悬液雾化吸入和口服强的松均能改善AECOPD的肺功能,布地奈德混悬液雾化吸入治疗AECOPD的安全性较口服强的松好.Objective： To study the therapeutic effect of inhaling nebulization budesonide in acute exacerbation of chronic obstructive pulmonary disease （AECOPD）, and the comparativity of the clinical effects and safety with oral glucocorticoid （prednisone）. Methods. 92 patients with AECOPD were randomly divided into 3 groups which were A, B and C. All the three groups were administered with basic therapy of anti-infection, theophylline, oxygen inhalation, sputum aspiration and so on. Group A was treated with inhaling nebulization budesonide suspension （n = 31）, group B was treated with oral prednisone （n = 31）, and group C was a control group with basic therapy （n = 30）. The clinical grade, St George＇s respiration questionnaire living quality grade, PEF, FVC, blood gas analysis and glucocorticoid relative adverse reaction were recorded before the treatment （H0）, after the treatment at 24 h （H24） and 7 days （D7） in every group. Results： No significant difference in all three groups at H0 （P 〉 0.05）, obvious improvements were observed at H24, D7 in group A and B, with no significant difference between group A and B. Less side effects in group A than that in group B. Compared to group A and B, situation in group C was improved but had significant differences with group A and B. Conclusion： Inhaling nebulization budesonide suspension in COPD can exactly shorten the course of disease conveniently and safely, and can be used as the major medicine of COPD. Both inhaling nebulization budesonide suspension and oral prednisone can enhance the pulmonary functions of AECOPD patients. Budesonide suspension is more effective and has less side-effect for treatment of AECOPD.

关 键 词：布地奈德混悬液(普米克令舒) 慢性阻塞性肺疾病急性加重期 雾化吸入 强的松 

分 类 号：R563.05[医药卫生—呼吸系统]